Literature DB >> 2284689

Mononuclear cell infiltrate and HLA-Dr expression in 28 pituitary adenomas.

M L Rossi1, N R Jones, M M Esiri, L Havas, M al Izzi, H B Coakham.   

Abstract

Frozen sections from 28 pituitary adenomas were reached with a panel of monoclonal antibodies to macrophages, lymphocytes and HLA-Dr invariant chain. A low number of macrophages were demonstrated in all tumors, mainly perivascular. CD8 and CD4 lymphocytes were detected in even smaller numbers in 80% and 14% of tumors respectively. B lymphocytes were present in only 1 case. An occasional NK cell was present in 1/13 cases studied. HLA-Dr antigen was expressed by macrophages in all cases and by tumor cells in 2 growth hormone-producing adenomas/19 adenomas. These findings may represent evidence for a low degree of cellular immune response to pituitary adenomas.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2284689     DOI: 10.1177/030089169007600605

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  8 in total

1.  Immune Cell Infiltrates in Pituitary Adenomas: More Macrophages in Larger Adenomas and More T Cells in Growth Hormone Adenomas.

Authors:  Jian-Qiang Lu; Benjamin Adam; Andrew S Jack; Anna Lam; Robert W Broad; Constance L Chik
Journal:  Endocr Pathol       Date:  2015-09       Impact factor: 3.943

Review 2.  The Microenvironment of Pituitary Tumors-Biological and Therapeutic Implications.

Authors:  Mirela Diana Ilie; Alexandre Vasiljevic; Gérald Raverot; Philippe Bertolino
Journal:  Cancers (Basel)       Date:  2019-10-21       Impact factor: 6.639

3.  Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours.

Authors:  Pedro Marques; Sayka Barry; Eivind Carlsen; David Collier; Amy Ronaldson; Sherine Awad; Neil Dorward; Joan Grieve; Nigel Mendoza; Samiul Muquit; Ashley B Grossman; Frances Balkwill; Márta Korbonits
Journal:  Acta Neuropathol Commun       Date:  2019-11-08       Impact factor: 7.801

4.  Lactate-induced M2 polarization of tumor-associated macrophages promotes the invasion of pituitary adenoma by secreting CCL17.

Authors:  Anke Zhang; Yuanzhi Xu; Houshi Xu; Jie Ren; Tong Meng; Yunjia Ni; Qingwei Zhu; Wen-Bo Zhang; Yuan-Bo Pan; Jiali Jin; Yunke Bi; Zhe Bao Wu; Shaojian Lin; Meiqing Lou
Journal:  Theranostics       Date:  2021-02-06       Impact factor: 11.556

Review 5.  The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.

Authors:  Congxin Dai; Siyu Liang; Bowen Sun; Jun Kang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-11       Impact factor: 5.555

Review 6.  Research advances on the immune research and prospect of immunotherapy in pituitary adenomas.

Authors:  Ding Nie; Qiuyue Fang; Bin Li; Jianhua Cheng; Chuzhong Li; Songbai Gui; Yazhuo Zhang; Peng Zhao
Journal:  World J Surg Oncol       Date:  2021-06-05       Impact factor: 2.754

7.  Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors.

Authors:  Yu Mei; Wenya Linda Bi; Noah F Greenwald; Ziming Du; Nathalie Y R Agar; Ursula B Kaiser; Whitney W Woodmansee; David A Reardon; Gordon J Freeman; Peter E Fecci; Edward R Laws; Sandro Santagata; Gavin P Dunn; Ian F Dunn
Journal:  Oncotarget       Date:  2016-11-22

8.  Alterations in CD8+ Tregs, CD56+ Natural Killer Cells and IL-10 Are Associated With Invasiveness of Nonfunctioning Pituitary Adenomas (NFPAs).

Authors:  Xinmei Huang; Jiong Xu; Yueyue Wu; Li Sheng; Yue Li; Bingbing Zha; Tiange Sun; Ju Yang; Shufei Zang; Jun Liu
Journal:  Pathol Oncol Res       Date:  2021-03-25       Impact factor: 3.201

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.